ERBB2 and breast cancer: Only the TBCRC 022 study allowed the inclusion of patients with LM while investigating the efficacy of neratinib plus capecitabine in HER2-positive BC with brain metastases (BM), and three patients with LM had progressive disease, partial response, and stable disease, respectively.